Home » Authors » Tom Wall

Tom Wall

Articles

ARTICLES

Tranzyme Jumps into IPO Queue, Files for $75M Offering

Nov. 24, 2010

Regeneron Stock Up 19.7% After Positive VEGF Trap-Eye Report

Nov. 23, 2010

The talk from Regeneron Pharmaceuticals Inc. is of trials – clinical and, perhaps, legal. (BioWorld Today)

Archemix Could Get $315M in Baxter Hemophilia Assets Deal

Nov. 22, 2010

Sekisui Buys Genzyme's Diagnostic Unit for $265M

Nov. 19, 2010

It was biotech's version of "buy-one-get-one" for Genzyme business units on Thursday. (BioWorld Today)

Forma Will Get $20M from Eisai in Drug Discovery Deal

Nov. 18, 2010

Aires Gives Novartis $250M Option, Gets $20M Series B

Nov. 15, 2010

Micromet Shares Dip $1 After Pricing $72M Offering

Nov. 12, 2010

Agenta's Proteoglycan Delivery Technology Regenerates Bone

Nov. 11, 2010

LFB Biotechnologies to Take GTC Biotherapeutics Private

Nov. 9, 2010

Karyopharm's $20M Series A Will Finance SINE Candidates

Nov. 4, 2010

View All Articles by Tom Wall

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...